Journal Mobile Options
Table of Contents
Vol. 45, No. 1, 2010
Issue release date: September 2010

GSH Attenuates Organ Injury and Improves Function after Transplantation of Fatty Livers

Pratschke S. · Angele M.K. · Grützner U. · Tufman A. · Bilzer M. · Loehe F. · Jauch K.-W. · Schauer R.J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Ischemia-reperfusion injury (IRI) is increased after transplantation of steatotic livers. Since those livers are increasingly used for transplantation, protective strategies must be developed. Reactive oxygen species (ROS) play a key role in hepatic IRI. In lean organs, glutathione (GSH) is an efficient scavenger of ROS, diminishing IRI. The aim of this study was to evaluate whether GSH also protects steatotic allografts from IRI following transplantation. Fatty or lean livers were explanted from 10-week-old obese or lean Zucker rats and preserved (obese 4 h, lean 24 h) in hypothermic University of Wisconsin solution. Arterialized liver transplantation was then performed in lean syngeneic Zucker rats. Recipients of fatty livers were treated with GSH (200 µmol/h/kg) or saline during reperfusion (2 h, n = 5). Parameters of hepatocellular damage and bile flow were measured. Transplantation of steatotic livers enhanced early reperfusion injury compared to lean organs as measured by increased aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase plasma levels. Bile flow was also reduced in steatotic grafts. Intravenous administration of GSH effectively decreased liver damage in fatty allografts and resulted in improved bile flow. Intravenous application of GSH effectively reduces early IRI in steatotic allografts and improves recovery of these marginal donor organs following transplantation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JE, et al: Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996;62:1246–1251.
  2. Koneru B, Dikdan G: Hepatic steatosis and liver transplantation current clinical and experimental perspectives. Transplantation 2002;73:325–330.
  3. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA: Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007;246:940–946.
  4. Angele MK, Rentsch M, Hartl WH, Wittmann B, Graeb C, Jauch KW, et al: Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg 2008;195:214–220.
  5. Soltys K, Dikdan G, Koneru B: Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2001;34:13–18.
  6. Amersi F, Shen XD, Moore C, Melinek J, Busuttil RW, Kupiec-Weglinski JW, et al: Fibronectin-alpha 4 beta 1 integrin-mediated blockade protects genetically fat Zucker rat livers from ischemia/reperfusion injury. Am J Pathol 2003;162:1229–1239.
  7. Bilzer M, Paumgartner G, Gerbes AL: GSH protects the rat liver against reperfusion injury after hypothermic preservation. Gastroenterology 1999;117:200–210.
  8. Jaeschke H: Mechanisms of liver injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 2006;290:G1083–G1088.
  9. Bilzer M, Baron A, Schauer R, Steib C, Ebensberger S, Gerbes AL: GSH treatment protects the rat liver against injury after warm ischemia and Kupffer cell activation. Digestion 2002;66:49–57.
  10. Schauer RJ, Kalmuk S, Gerbes AL, Leiderer R, Meissner H, Schildberg FW, et al: Intravenous administration of GSH protects parenchymal and non-parenchymal liver cells against reperfusion injury following rat liver transplantation. World J Gastroenterol 2004;10:864–870.
  11. Selzner M, Rudiger HA, Sindram D, Madden J, Clavien PA: Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000;32:1280–1288.
  12. Amersi F, Farmer DG, Shaw GD, Kato H, Coito AJ, Kaldas F, et al: P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am J Transplant 2002;2:600–608.
  13. Bradham CA, Schemmer P, Stachlewitz RF, Thurman RG, Brenner DA: Activation of nuclear factor-kappaB during orthotopic liver transplantation in rats is protective and does not require Kupffer cells. Liver Transpl Surg 1999;5:282–293.
  14. Schemmer P, Bradford BU, Rose ML, Bunzendahl H, Raleigh JA, Lemasters JJ, et al: Intravenous glycine improves survival in rat liver transplantation. Am J Physiol 1999;276:G924–G932.
  15. Kamada N, Calne RY: A surgical experience with 530 liver transplants in the rat. Surgery 1983;93:64–69.
  16. Post S, Gonzalez AP, Palma P, Rentsch M, Stiehl A, Menger MD: Assessment of hepatic phagocytic activity by in vivo microscopy after liver transplantation in the rat. Hepatology 1992;16:803–809.
  17. Schauer RJ, Bilzer M, Kalmuk S, Gerbes AL, Leiderer R, Schildberg FW, et al: Microcirculatory failure after rat liver transplantation is related to Kupffer cell-derived oxidant stress but not involved in early graft dysfunction. Transplantation 2001;72:1692–1699.
  18. Jaeschke H, Mitchell JR: Use of isolated perfused organs in hypoxia and ischemia/reperfusion oxidant stress. Methods Enzymol 1990;186:752–759.
  19. Tietze F: Enzymic method for quantitative determination of nanogram amounts of total and oxidized GSH: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502–522.
  20. Bergmeyer HU, Horder M, Rej R: International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC J Clin Chem Clin Biochem 1986;24:481–495.
  21. Bais R, Philcox M: Approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 8. IFCC Method for Lactate Dehydrogenase (L-Lactate: NAD+Oxidoreductase, EC International Federation of Clinical Chemistry (IFCC). Eur J Clin Chem Clin Biochem 1994;32:639–655.
  22. Reddy MC, Koneru B, Soni S, Patel D: 31P nuclear magnetic resonance study of phospholipids in ischemia/reperfusion injury in a rat fatty liver model. Transplantation 1996;61:1151–1155.
  23. Teramoto K, Bowers JL, Kruskal JB, Clouse ME: Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation 1993;56:1076–1082.
  24. Selzner M, Clavien PA: Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001;21:105–113.
  25. Sun CK, Zhang XY, Zimmermann A, Davis G, Wheatley AM: Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. Transplantation 2001;72:1625–1631.
  26. Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckels J, et al: 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006;367:225–232.
  27. Afonso RC, Hidalgo R, Paes AT, Zurstrassen MP, Fonseca LE, Pandullo FL, et al: Impact of cumulative risk factors for expanded criteria donors on early survival after liver transplantation. Transplant Proc 2008;40:800–801.
  28. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, et al: Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996;13:18–19.
  29. Nardo B, Caraceni P, Pasini P, Domenicali M, Catena F, Cavallari G, et al: Increased generation of reactive oxygen species in isolated rat fatty liver during postischemic reoxygenation. Transplantation 2001;71:1816–1820.
  30. Lehmann TG, Wheeler MD, Schwabe RF, Connor HD, Schoonhoven R, Bunzendahl H, et al: Gene delivery of Cu/Zn-superoxide dismutase improves graft function after transplantation of fatty livers in the rat. Hepatology 2000;32:1255–1264.
  31. Choi S, Noh J, Hirose R, Ferell L, Bedolli M, Roberts JP, et al: Mild hypothermia provides significant protection against ischemia/reperfusion injury in livers of obese and lean rats. Ann Surg 2005;241:470–476.
  32. Schauer RJ, Gerbes AL, Vonier D, Meissner H, Michl P, Leiderer R, et al: GSH protects the rat liver against reperfusion injury after prolonged warm ischemia. Ann Surg 2004;239:220–231.
  33. Lauterburg BH, Adams JD, Mitchell JR: Hepatic GSH homeostasis in the rat: efflux accounts for GSH turnover. Hepatology 1984;4:586–590.
  34. Bilzer M, Lauterburg BH: GSH metabolism in activated human neutrophils: stimulation of GSH synthesis and consumption of GSH by reactive oxygen species. Eur J Clin Invest 1991;21:316–322.
  35. Aebi S, Assereto R, Lauterburg BH: High-dose intravenous GSH in man: pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest 1991;21:103–110.
  36. Akerboom TP, Gartner M, Sies H: Cellular hydroperoxide metabolism: the roles of GSH peroxidases and of catalase in liver. Bull Eur Physiopathol Respir 1981;17(suppl):221–227.

    External Resources

  37. Dickinson DA, Forman HJ: GSH in defense and signaling: lessons from a small thiol. Ann NY Acad Sci 2002;973:488–504.
  38. Seifalian AM, Piasecki C, Agarwal A, Davidson BR: The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999;68:780–784.
  39. Serkova NJ, Jackman M, Brown JL, Liu T, Hirose R, Roberts JP, et al: Metabolic profiling of livers and blood from obese Zucker rats. J Hepatol 2006;44:956–962.
  40. Yamagami K, Hutter J, Yamamoto Y, Schauer RJ, Enders G, Leiderer R, et al: Synergistic effects of brain death and liver steatosis on the hepatic microcirculation. Transplantation 2005;80:500–505.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50